MaxCyte

Historical price data

MaxCyte's mission is to accelerate the development of advanced cell and gene therapies by providing best-in-class, scalable cell engineering technology. Its key achievement is having its platform used in the manufacturing process for the first-ever globally approved non-viral CRISPR-based therapy, validating its industrial and clinical relevance. The company's strategy centers on a partnership-driven licensing model, providing its ExPERT electroporation platform and SeQure gene editing risk assessment services to therapy developers, thereby generating revenue through instrument sales, consumables, and clinical/commercial milestone payments.

Proprietary Flow Electroporation® technology delivered through the ExPERT instrument suite, enabling high-efficiency, scalable, non-viral transfection of diverse cell types for cell and gene therapy development.

MaxCyte's primary competitors include Lonza (Nucleofector) and Thermo Fisher Scientific (Neon) in the electroporation instrument space. Its key advantages are seamless clinical/commercial scalability, validation in a marketed therapy, and a deeply embedded partnership model that creates high switching costs for developers.